{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T08:10:41Z","timestamp":1784448641673,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40261-023-01270-x","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:01:48Z","timestamp":1683111708000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use"],"prefix":"10.1007","volume":"43","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"issue":"4","key":"1270_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.plipres.2013.05.001","volume":"52","author":"JP Slotte","year":"2013","unstructured":"Slotte JP. Biological functions of sphingomyelins. Prog Lipid Res. 2013;52(4):424\u201337.","journal-title":"Prog Lipid Res"},{"issue":"1\u20132","key":"1270_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann\u2013Pick disease. Mol Genet Metab. 2017;120(1\u20132):27\u201333.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"1270_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/gim.2017.7","volume":"19","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Dionisi-Vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19(9):967\u201374.","journal-title":"Genet Med"},{"issue":"212","key":"1270_CR4","first-page":"1","volume":"16","author":"MM McGovern","year":"2021","unstructured":"McGovern MM, Wasserstein MP, Bembi B, et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis. 2021;16(212):1\u201314.","journal-title":"Orphanet J Rare Dis"},{"issue":"41","key":"1270_CR5","first-page":"1","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, et al. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(41):1\u201313.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1270_CR6","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2007-3016","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann\u2013Pick disease type B. Pediatrics. 2008;122(2):e341\u20139.","journal-title":"Pediatrics"},{"issue":"8","key":"1270_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, et al. Morbidity and mortality in type B Niemann\u2013Pick disease. Genet Med. 2013;15(8):618\u201323.","journal-title":"Genet Med"},{"issue":"8","key":"1270_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/PAS.0b013e31825793ff","volume":"36","author":"BL Thurberg","year":"2012","unstructured":"Thurberg BL, Wasserstein MP, Schiano T, et al. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann\u2013Pick disease type B). Am J Surg Pathol. 2012;36(8):1234\u201346.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1270_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1067\/mpd.2003.113","volume":"142","author":"MP Wasserstein","year":"2003","unstructured":"Wasserstein MP, Larkin AE, Glass RB, et al. Growth restriction in children with type B Niemann\u2013Pick disease. J Pediatr. 2003;142(4):424\u20138.","journal-title":"J Pediatr"},{"issue":"3","key":"1270_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann\u2013Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118(3):206\u201313.","journal-title":"Mol Genet Metab"},{"key":"1270_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/8904_2018_120","volume":"41","author":"GF Cox","year":"2018","unstructured":"Cox GF, Clarke LA, Giugliani R, et al. Burden of illness in acid sphingomyelinase deficiency: a retrospective chart review of 100 patients. JIMD Rep. 2018;41:119\u201329.","journal-title":"JIMD Rep"},{"key":"1270_CR12","unstructured":"European Medicines Agency. Xenpozyme (olipudase alfa): European public assessment report; 2022. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/xenpozyme-epar-public-assessment-report_en.pdf. Accessed 25 Jan 2023."},{"issue":"2","key":"1270_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0167-4838(99)00069-2","volume":"1432","author":"X He","year":"1999","unstructured":"He X, Miranda SR, Xiong X, et al. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim Biophys Acta. 1999;1432(2):251\u201364.","journal-title":"Biochim Biophys Acta"},{"key":"1270_CR14","unstructured":"European Medicines Agency. Xenpozyme 20 mg powder for concentrate for solution for infusion: EU summary of product characteristics; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xenpozyme-epar-product-information_en.pdf. Accessed 25 Jan 2023."},{"key":"1270_CR15","unstructured":"Sanofi. XENPOZYME\u2122 (olipudase alfa-rpcp) for injection, for intravenous use: US prescribing information; 2022. https:\/\/products.sanofi.us\/xenpozyme\/xenpozyme.pdf. Accessed 25 Jan 2023."},{"key":"1270_CR16","unstructured":"Sanofi. Olipudase alfa (Xenpozyme\u2122) IV infusion: Japanese prescribing information; 2022. https:\/\/www.pmda.go.jp\/files\/000247409.pdf. Accessed 25 Jan 2023."},{"issue":"1\u20132","key":"1270_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ymgme.2015.05.013","volume":"116","author":"MP Wasserstein","year":"2015","unstructured":"Wasserstein MP, Jones SA, Soran H, et al. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab. 2015;116(1\u20132):88\u201397.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1270_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/gim.2015.24","volume":"18","author":"MM McGovern","year":"2016","unstructured":"McGovern MM, Wasserstein MP, Kirmse B, et al. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann\u2013Pick disease type B (acid sphingomyelinase deficiency). Genet Med. 2016;18(1):34\u201340.","journal-title":"Genet Med"},{"issue":"13","key":"1270_CR19","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1096\/fj.00-0014com","volume":"14","author":"SR Miranda","year":"2000","unstructured":"Miranda SR, He X, Simonaro CM, et al. Infusion of recombinant human acid sphingomyelinase into Niemann\u2013Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 2000;14(13):1988\u201395.","journal-title":"FASEB J"},{"issue":"9","key":"1270_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/PAS.0000000000000659","volume":"40","author":"BL Thurberg","year":"2016","unstructured":"Thurberg BL, Wasserstein MP, Jones SA, et al. Clearance of hepatic sphingomyelin by olipudase alfa is associated with improvement in lipid profiles in acid sphingomyelinase deficiency. Am J Surg Pathol. 2016;40(9):1232\u201342.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1270_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","volume":"41","author":"MP Wasserstein","year":"2018","unstructured":"Wasserstein MP, Diaz GA, Lachmann RH, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis. 2018;41(5):829\u201338.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"1270_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ymgme.2020.06.010","volume":"131","author":"BL Thurberg","year":"2020","unstructured":"Thurberg BL, Diaz GA, Lachmann RH, et al. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment. Mol Genet Metab. 2020;131(1\u20132):245\u201352.","journal-title":"Mol Genet Metab"},{"key":"1270_CR23","doi-asserted-by":"crossref","unstructured":"Lachmann R, Diaz GA, Wasserstein MP, et al. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults. Orphanet J Rare Dis. 2023 (in press).","DOI":"10.1186\/s13023-023-02700-x"},{"issue":"7","key":"1270_CR24","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Lachmann R, Hollak C, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results. Genet Med. 2022;24(7):1425\u201336.","journal-title":"Genet Med"},{"issue":"8","key":"1270_CR25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, Jones SA, Scarpa M, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2021;23(8):1543\u201350.","journal-title":"Genet Med"},{"issue":"1","key":"1270_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","volume":"17","author":"GA Diaz","year":"2022","unstructured":"Diaz GA, Giugliani R, Guffon N, et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. Orphanet J Rare Dis. 2022;17(1):437.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 3","key":"1270_CR27","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1016\/j.gim.2022.01.315","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Barbato A, Gallagher R, et al. Continued improvement in adults with acid sphingomyelinase deficiency after 2 years of olipudase alfa in the ASCEND placebo-controlled trial. Genet Med. 2022;24(Suppl 3):S176\u20137.","journal-title":"Genet Med"},{"issue":"2","key":"1270_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymgme.2014.07.005","volume":"114","author":"JM Murray","year":"2015","unstructured":"Murray JM, Thompson AM, Vitsky A, et al. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: the utility of animal models of disease in the toxicological evaluation of potential therapeutics. Mol Genet Metab. 2015;114(2):217\u201325.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"1270_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ymgme.2020.06.008","volume":"131","author":"SA Jones","year":"2020","unstructured":"Jones SA, McGovern M, Lidove O, et al. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Mol Genet Metab. 2020;131(1\u20132):116\u201323.","journal-title":"Mol Genet Metab"},{"key":"1270_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.100957","volume":"34","author":"YW Pan","year":"2023","unstructured":"Pan YW, Tsai MC, Yang CY, et al. Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: a single center experience in Taiwan. Mol Genet Metab Rep. 2023;34: 100957.","journal-title":"Mol Genet Metab Rep"},{"key":"1270_CR31","unstructured":"Sanofi. Xenpozyme\u2122 (olipudase alfa-rpcp); 2022. https:\/\/www.xenpozyme.com\/. Accessed 25 Jan 2023."},{"issue":"2","key":"1270_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","volume":"126","author":"M Wasserstein","year":"2019","unstructured":"Wasserstein M, Dionisi-Vici C, Giugliani R, et al. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Mol Genet Metab. 2019;126(2):98\u2013105.","journal-title":"Mol Genet Metab"},{"key":"1270_CR33","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2206440\/v1","author":"T Geberhiwot","year":"2022","unstructured":"Geberhiwot T, Wasserstein M, Wanninayake S, et al. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann\u2013Pick disease types A, B and A\/B). Res Sq. 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-2206440\/v1.","journal-title":"Res Sq"}],"updated-by":[{"DOI":"10.1007\/s40261-023-01293-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01270-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T16:01:06Z","timestamp":1690387266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01270-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01270-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-023-01293-4","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"13 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-023-01293-4","URL":"https:\/\/doi.org\/10.1007\/s40261-023-01293-4","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}